# A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

> **NCT05886634** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Dedifferentiated Liposarcoma
- Soft Tissue Sarcoma
- Sarcoma,Soft Tissue
- Sarcoma
- Recurrent Dedifferentiated Liposarcoma
- Unresectable Dedifferentiated Liposarcoma
- Metastatic Dedifferentiated Liposarcoma

## Interventions

- **DRUG:** Etrumadenant
- **DRUG:** Zimberelimab

## Key facts

- **NCT ID:** NCT05886634
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2027-05-23
- **Final completion:** 2027-05-23
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05886634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05886634, "A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT05886634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*